Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 6 56-6, 2004, Pages

  Ohta, Takafumi ^a   Hasebe, Naoyuki ^a   Tsuji, Shiro ^a   Izawa, Kazuma ^a   Jin, Yin Tie ^a   Kido, Shinsuke ^a   Natori, Syunsuke ^a   Sato, Motohiko ^a   Kikuchi, Kenjiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Bradykinin; Catecholamine; Nitric oxide; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR; BRADYKININ ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; ISOPRENALINE; OLMESARTAN; TEMOCAPRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DISEASE EXACERBATION; DOG; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; HEART ATRIUM PACING; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ACUTE DISEASE; ALDOSTERONE; ANGIOTENSIN II; ANIMALS; ATRIAL NATRIURETIC FACTOR; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE, CONGESTIVE; ISOPROTERENOL; LIPID PEROXIDATION; MALE; RECEPTORS, ADRENERGIC, BETA; RENIN; RENIN-ANGIOTENSIN SYSTEM; SYMPATHOMIMETICS; VENTRICULAR FUNCTION, LEFT;

EID: 9444261868     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00221.2004     Document Type: Article

References (44)

1. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 97: 2202-2212, 1998.
2. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, and Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 32: 514-520, 1998.
3. Avanzini F, Ferrario G, Santoro L, Peci P, Giani P, Santoro E, Franzosi MG, and Tognoni G. Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database. Am Heart J 144: 1018-1025, 2002.
4. Balcells E, Meng QC, Johnson WH Jr, Oparil S, and Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol Heart Circ Physiol 213: H1769-H1774, 1997.
5. Baydoun AR and Woodward B. Effects of bradykinin in the rat isolated perfused heart: role of kinin receptors and endothelium-derived relaxing factor. Br J Pharmacol 103: 1829-1833, 1991.
6. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, and Clark WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. Circ Res 65: 657-670, 1989.
7. Brady AJ, Warren JB, Poole-Wilson PA, Williams TJ, and Harding SE. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol Heart Circ Physiol 265: H176-H182, 1993.
8. Brasch H, Sieroslawski L, and Dominiak P. Angiotensin II increases norepinephrine release from atria by acting on angiotensin subtype 1 receptors. Hypertension 22: 699-704, 1993.
9. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, and Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307: 205-211, 1982.
10. Brodde OE. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203-242, 1991.
11. Campbell WB and Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84: 484-488, 1999.
12. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, and Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823, 1984.
13. Communal C, Singh K, Pimentel DR, and Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98: 1329-1334, 1998.
14. Dickstein K and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360: 752-760, 2002.
15. Du XJ, Cox HS, Dart AM, and Esler MD. Depression of efferent parasympathetic control of heart rate in rats with myocardial infarction: effect of losartan. J Cardiovasc Pharmacol 31: 937-944, 1998.
16. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, and Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE Inhibitor Myocardial Infarction Collaborative Group. Lancet 355: 1575-1581, 2000.
17. Fulton D, Mahboubi K, McGiff JC, and Quilley J. Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol 114: 99-102, 1995.
18. Hare JM, Loh E, Creager MA, and Colucci WS. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 92: 2198-2203, 1995.
19. Hasebe N, Shen YT, Kiuchi K, Hittinger L, Bishop SP, and Vatner SF. Enhanced postischemic dysfunction selective to subendocardium in conscious dogs with LV hypertrophy. Am J Physiol Heart Circ Physiol 266: H702-H713, 1994.
20. Hasebe N, Shen YT, and Vatner SF. Inhibition of endothelium-derived relaxing factor enhances myocardial stunning in conscious dogs. Circulation 88: 2862-2871, 1993.
21. Hecker M, Bara AT, Bauersachs J, and Busse R. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol 481: 407-414, 1994.
22. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, Tatge H, and Drexler H. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 103: 799-805, 2001.
23. 1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 39: 401-412, 1998.
24. 1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res 35: 223-232, 1997.
25. Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, and Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 29: 859-870, 1997.
26. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, and Jeejeebhoy KN. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31: 1352-1356, 1998.
27. Khaper N and Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in M1 rats. J Am Coll Cardiol 37: 1461-1466, 2001.
28. Kudej RK, Iwase M, Uechi M, Vatner DE, Oka N, Ishikawa Y, Shannon RP, Bishop SP, and Vatner SF. Effects of chronic beta-adrenergic receptor stimulation in mice. J Mol Cell Cardiol 29: 2735-2746, 1997.
29. Linz W and Scholkens BA. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 20 Suppl 9: S83-S90, 1992.
30. Linz W, Wiemer G, and Scholkens BA. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size. Am J Cardiol 80: 118A-123A, 1997.
31. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, and Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100: 1056-1064, 1999.
32. Natori S, Hasebe N, Jin YT, Matsusaka T, Ido A, Matsuhashi H, Ihara T, and Kikuchi K. Inhaled nitric oxide modifies left ventricular diastolic stress in the presence of vasoactive agents in heart failure. Am J Respir Crit Care Med 167: 895-901, 2003.
33. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, and Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906, 2003.
34. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, and Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587, 2000.
35. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, and Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study. ELITE). Lancet 349: 747-752, 1997.
36. Powers FM, Pifarre R, and Thomas JX Jr. Ventricular dysfunction in norepinephrine-induced cardiomyopathy. Circ Shock 43: 122-129, 1994.
37. Rastaldo R, Paolocci N, Chiribiri A, Penna C, Gattullo D, and Pagliaro P. Cytochrome P-450 metabolite of arachidonic acid mediates bradykinin-induced negative inotropic effect. Am J Physiol Heart Circ Physiol 280: H2823-H2832, 2001.
38. Schrier RW and Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 341: 577-585, 1999.
39. Spinale FG, de Gasparo M, Whitebread S, Hebbar L, Clair MJ, Melton DM, Krombach RS, Mukherjee R, Iannini JP, and O S-J. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricular performance and neurohormonal systems. Circulation 96: 2385-2396, 1997.
40. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, and Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327: 678-684, 1992.
41. Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, Shimokawa H, Sueishi K, and Takeshita A. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 30: 1621-1627, 1997.
42. Wittstein IS, Kass DA, Pak PH, Maughan WL, Fetics B, and Hare JM. Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy. J Am Coll Cardiol 38: 429-435, 2001.
43. Yamamoto S, Tsutsui H, Tagawa H, Saito K, Takahashi M, Tada H, Yamamoto M, Katoh M, Egashira K, and Takeshita A. Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure. Circulation 95: 1111-1114, 1997.
44. Zimmerman BG, Gomer SK, and Liao JC. Action of angiotensin on vascular adrenergic nerve endings: facilitation of norepinephrine release. Fed Proc 31: 1344-1350, 1972.